Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Workman

Showing results (241-250 of 268) with videos related to

Pageof 27
Sort By:
Molecular Pharmacology|May 1, 1995
Catalytic properties of NAD(P)H:quinone acceptor oxidoreductase: study involving mouse, rat, human, and mouse-rat chimeric enzymesS Chen, R Knox, A D Lewis, et al.
British Journal of Cancer|December 1, 1988
High dose BCNU chemotherapy with autologous bone marrow transplantation and full dose radiotherapy for grade IV astrocytomaE K Mbidde, P J Selby, T J Perren, et al.
British Journal of Cancer|May 20, 2004
In vivo evaluation of [18F]fluoroetanidazole as a new marker for imaging tumour hypoxia with positron emission tomographyH Barthel, H Wilson, D R Collingridge, et al.
Current Medicinal Chemistry|June 9, 2011
Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitorsS J Shuttleworth, F A Silva, A R L Cecil, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 1, 1997
Phase I and pharmacokinetic study of tirapazamine (SR 4233) administered every three weeksS Senan, R Rampling, M A Graham, et al.
Cancer Research|August 1, 1997
Preclinical evaluation of the fluorinated 2-nitroimidazole N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR-4554) as a probe for the measurement of tumor hypoxiaE O Aboagye, R J Maxwell, A B Kelson, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1997
Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a phase I trialM A Graham, S Senan, H Robin, et al.
The British Journal of Radiology|October 1, 1986
A comparative study of Ro 03-8799: racemic mixture and enantiomersH F Newman, E P Dunphy, N M Bleehen, et al.
British Journal of Cancer|October 1, 1985
Establishment and characterisation of cell lines from patients with lung cancer (predominantly small cell carcinoma)H Baillie-Johnson, P R Twentyman, N E Fox, et al.
Biochimica Et Biophysica Acta|January 20, 1998
Inhibition of phospholipid signalling and proliferation of Swiss 3T3 cells by the wortmannin analogue demethoxyviridinM J Cross, M N Hodgkin, J A Plumb, et al.
Pageof 27

Showing results (241-250 of 268) with videos related to

Sort By:
Pageof 27
Molecular Pharmacology|May 1, 1995
Catalytic properties of NAD(P)H:quinone acceptor oxidoreductase: study involving mouse, rat, human, and mouse-rat chimeric enzymesS Chen, R Knox, A D Lewis, et al.
British Journal of Cancer|December 1, 1988
High dose BCNU chemotherapy with autologous bone marrow transplantation and full dose radiotherapy for grade IV astrocytomaE K Mbidde, P J Selby, T J Perren, et al.
British Journal of Cancer|May 20, 2004
In vivo evaluation of [18F]fluoroetanidazole as a new marker for imaging tumour hypoxia with positron emission tomographyH Barthel, H Wilson, D R Collingridge, et al.
Current Medicinal Chemistry|June 9, 2011
Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitorsS J Shuttleworth, F A Silva, A R L Cecil, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 1, 1997
Phase I and pharmacokinetic study of tirapazamine (SR 4233) administered every three weeksS Senan, R Rampling, M A Graham, et al.
Cancer Research|August 1, 1997
Preclinical evaluation of the fluorinated 2-nitroimidazole N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR-4554) as a probe for the measurement of tumor hypoxiaE O Aboagye, R J Maxwell, A B Kelson, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1997
Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a phase I trialM A Graham, S Senan, H Robin, et al.
The British Journal of Radiology|October 1, 1986
A comparative study of Ro 03-8799: racemic mixture and enantiomersH F Newman, E P Dunphy, N M Bleehen, et al.
British Journal of Cancer|October 1, 1985
Establishment and characterisation of cell lines from patients with lung cancer (predominantly small cell carcinoma)H Baillie-Johnson, P R Twentyman, N E Fox, et al.
Biochimica Et Biophysica Acta|January 20, 1998
Inhibition of phospholipid signalling and proliferation of Swiss 3T3 cells by the wortmannin analogue demethoxyviridinM J Cross, M N Hodgkin, J A Plumb, et al.
Pageof 27